Pharmsville팜스빌
318010 · KOSDAQ · ₩318010 · 팜스빌
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩2,684
vs the current price (₩3,390)
- Enterprise value
- ₩4.4B
- Equity value
- ₩21B
- WACC
- 7.3%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- ₩2,398
- −29.3%
- Base
- ₩2,684
- −20.8%
- Bull
- ₩3,231
- −4.7%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (4.1%).
Revenue growth
- -10%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-21.3% a year, annual reports), fading to 3% by year 5.
- -6.7%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-21.3% a year, annual reports), fading to 3% by year 5.
- -3.5%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-21.3% a year, annual reports), fading to 3% by year 5.
- -0.2%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-21.3% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-21.3% a year, annual reports), fading to 3% by year 5.
Business
- 4.1%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 0.7%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 0.9%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 40%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.01%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-30.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 104 weeks of weekly returns against KOSPI (official index); raw beta 0.02, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.51%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩11B
- Net debt (borrowings and leases − cash and deposits)
- −₩5.2B
- + Stakes and investments
- ₩12B
- Associates, long-term financial assets and deposits (book value)
- − Minority interests
- ₩134M
- Shares
- 7,929,338
- Share price
- ₩3,390
- Market cap
- ₩27B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩21B | ₩17B | ₩13B | ₩10B | ₩9.4B | ₩9.1B | ₩9.1B | ₩9.3B |
| Growth | −18.1% | −21.8% | −23.9% | −10.0% | −6.7% | −3.5% | −0.2% | 3.0% |
| EBIT | ₩1.6B | −₩258M | −₩673M | ₩413M | ₩386M | ₩372M | ₩371M | ₩383M |
| EBIT margin | 7.6% | −1.5% | −5.3% | 4.1% | 4.1% | 4.1% | 4.1% | 4.1% |
| After-tax EBIT | ₩1.2B | −₩187M | −₩488M | ₩300M | ₩280M | ₩270M | ₩269M | ₩277M |
| + Depreciation | — | — | — | ₩71M | ₩66M | ₩64M | ₩63M | ₩65M |
| − Capital spending | ₩293M | ₩105M | ₩71M | ₩91M | ₩85M | ₩82M | ₩82M | ₩84M |
| − Working capital | ₩5.6B | −₩11B | ₩16B | −₩448M | −₩270M | −₩132M | −₩7.3M | ₩109M |
| Free cash flow | — | — | — | ₩728M | ₩531M | ₩383M | ₩258M | ₩150M |
| Discount factor | — | — | — | 0.932 | 0.868 | 0.809 | 0.754 | 0.703 |
| Present value | — | — | — | ₩678M | ₩461M | ₩310M | ₩195M | ₩105M |
Terminal value ₩3.8B, worth ₩2.6B today: 60% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩8,394 a share)Now 0.40× | ₩3,4970.42× | ₩6,8520.82× | ₩15,3531.83× |
| Price / earnings (last 12 months: ₩377 a share)Now 8.99× | ₩3,4929.26× | ₩6,44717.1× | ₩11,64230.9× |
| P/E on run-rate earnings (Q2 2026 × 4: ₩235 a share)Now 14.4× | ₩2,1799.26× | ₩4,02317.1× | ₩7,26530.9× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.3% | ₩2,767 | ₩2,776 | ₩2,786 | ₩2,798 | ₩2,814 |
| 6.8% | ₩2,720 | ₩2,725 | ₩2,730 | ₩2,735 | ₩2,742 |
| 7.3% | ₩2,681 | ₩2,682 | ₩2,684 | ₩2,685 | ₩2,686 |
| 7.8% | ₩2,647 | ₩2,647 | ₩2,646 | ₩2,644 | ₩2,642 |
| 8.3% | ₩2,618 | ₩2,616 | ₩2,614 | ₩2,610 | ₩2,606 |
Now (TTM)
- Market cap
- ₩27B
- Enterprise value
- ₩22B
- P/E
- 9.0×
- P/B
- 0.4×
- P/S
- 2.4×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩3,435 | ₩3,745 | ₩8,650 | ₩10,900 | ₩13,700 |
| Market cap | ₩27B | ₩30B | ₩69B | ₩86B | ₩109B |
| P/E | 9.4× | 18.8× | 20.7× | 21.3× | 21.7× |
| P/B | 0.4× | 0.5× | 1.1× | 1.4× | 1.8× |
| P/S | 2.1× | 1.8× | 3.2× | 3.3× | 2.8× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 0.0% | 0.0% | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Pharmsville | 9.0× | 0.4× | 2.4× | — | 0.0% |
| Samyang Foods | 17.6× | 5.6× | 3.1× | — | 0.4% |
| Orion | 10.8× | 1.1× | 1.3× | 5.4× | 3.0% |
| CJ Cheiljedang | — | 0.3× | 0.1× | — | 3.5% |
| Nongshim | 12.3× | 0.8× | 0.7× | — | 1.5% |
| Otoki | 17.4× | 0.6× | 0.3× | — | 2.8% |
| Hite Jinro | 23.7× | 1.0× | 0.5× | 6.4× | 4.4% |
| Similar companies (median) | 17.4× | 0.9× | 0.6× | 5.9× | 2.9% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Pharmsville / 팜스빌 / 318010 / KRX:318010
Source: KRX statistical information